Results 191 to 200 of about 1,285,317 (373)
ESC Heart Failure, EarlyView.Abstract Aims Cardiopulmonary bypass (CPB) is the standard approach for coronary artery bypass grafting (CABG) in advanced ischaemic cardiomyopathy. Microaxial pump support has been envisioned to allow for beating‐heart CABG without CPB (MPCAB), thereby avoiding CPB‐inherent complications.
Anna Kathrin Assmann +5 more
wiley +1 more source
Regression of coronary atherosclerosis: is it possible? [PDF]
, 1988 J. Shepherd, C.J. Packard
openalex +1 more source
Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi +3 more
wiley +1 more source
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients
ESC Heart Failure, EarlyView.Abstract Aims Malnutrition is increasingly recognized as a significant factor influencing the clinical outcomes of patients with heart failure (HF). Diabetes exacerbates risks like hospitalizations and mortality due to cardiovascular complications. The aim of this study was to explore the association of malnutrition with diabetes and its prognostic ...
Konstantinos Prokopidis +8 more
wiley +1 more source
Aneurysm of Sinus of Valsalva with Coronary Atherosclerosis
, 1979 Michael E. DeBakey, Gerald M. Lawrie
openalex +2 more sources
ESC Heart Failure, EarlyView.Abstract Aims Gut dysbiosis is proven to be involved in the pathogenesis and progression of heart failure (HF). Hindering the detrimental effects of gut‐heart axis is an emerging trend. Our goal is to investigate the causal relationship between gut microbiota and HF, with the aim of facilitating future exploration of microbiome‐targeted approaches to ...
Liyan Huang +8 more
wiley +1 more source
Journal of Tehran University Heart Center, 2015 Letter to the ...
Toba Kazemi, GholamReza Sharifzadeh
doaj
Racial differences in platelet survival time in patients with symptomatic coronary atherosclerosis. [PDF]
, 1983 L C Thomas +4 more
openalex +1 more source
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
ESC Heart Failure, EarlyView.Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna +4 more
wiley +1 more source